DOCSLIB.ORG

I SUMMARY of CHANGES

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
I SUMMARY of CHANGES SUMMARY OF CHANGES – Protocol For Protocol Amendment #3 to: A Phase 2 Study of Nivolumab in Advanced Leiomyosarcoma of the Uterus NCI Protocol #: 9672 Local Protocol #: DFCI- 15-707 NCI Version Date: Protocol Date: 27 April 2018 Please provide a list of changes from the previous CTEP approved version of the protocol. The list shall identify by page and section each change made to a protocol document with hyperlinks to the section in the protocol document. All changes shall be described in a point-by-point format (i.e., Page 3, section 1.2, replace ‘xyz’ and insert ‘abc’). When appropriate, a brief justification for the change should be included. Secti # Page(s) Change on 1. N/A 1 The protocol version number and date have been updated to Version 3/ Beginning April 1, 2018, the study has converted from the use of 5.8 31 CTCAE v4.0 to CTCAE v5.0 for adverse event reporting. The protocol 2. has been updated to reflect this change. 7.2 51 (Please retain the section break below, so that the Title Page is page “1” of the document.) i NCI Protocol #: 9672 Local Protocol #: DFCI- 15-707 ClinicalTrials.gov Identifier: NCT02428192 TITLE: A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus Corresponding Organization: Dana-Farber Harvard Cancer Center Principal Investigator: Suzanne George Dana-Farber Cancer Institute 450 Brookline Ave Boston, MA 02115 617-632-5204 617-632-3408 [email protected] Participating Organizations LAO-MA036 / Dana-Farber - Harvard Cancer Center LAO Statistician: Study Coordinator: Constance Barysauskas Sarah Solomon Dana-Farber Cancer Institute Dana-Farber Cancer Institute 450 Brookline Ave 450 Brookline Ave Boston, MA Boston, MA 617-582-9055 617-582-7503 [email protected] [email protected] Responsible Research Nurses: Melissa Hohos, RN Dana-Farber Cancer Institute 450 Brookline Ave P: 617-582-7162 F: 617-632-3408 E: [email protected] NCI-Supplied Agents: Nivolumab (BMS-936558, MDX-1106, and ONO-4538) NSC #748726; Ipilimumab (BMS-743016; MDX-010 Transfectoma-derived) NSC #732442 1 IND #: 125336 IND Sponsor: DCTD, NCI Protocol Type / Version # / Version Date: Original / Version#3 / 27 April 2018 2 SCHEMA COHORT A 3 Screen Enroll if eligible Nivolumab 3mg/kg administered every 2 weeks Immune correlates drawn per study calendar Baseline Assessments Week 4-6 Week 12 Tumor biopsy (min of Tumor assessment per Baseline Tumor 10 pts) RECIST RECIST per CT/MRI Tumor biopsy (min. 10 pts) Immune Correlatives CR, PR, SD per RECIST 1.1 PD per RECIST 1.1 Continue on study, Off study* Nivolumab 3mg/kg every 2 wks *some pts may remain on study post RECIST PD as noted in protocol RECIST per CT/MRI every 12 weeks SCHEMA COHORT B 4 Screen Nivolumab 3mg/kg plus ipilimumab 1mg/kg administered every 3 weeks for four Enroll if eligible cycles, then nivolumab 3mg/kg every 2 weeks Immune correlates drawn per study calendar Baseline Assessments Week 4-6 Week 8 Tumor biopsy Tumor assessment per Baseline Tumor RECIST RECIST per CT/MRI Tumor biopsy Immune Correlatives CR, PR, SD per RECIST 1.1 PD per RECIST 1.1 Nivolumab 3mg/kg plus ipilimumab Off study* 1mg/kg every 3 weeks to complete 12 weeks, then nivolumab 3mg/kg every 2 *some pts may remain on weeks study post RECIST PD as noted in protocol RECIST per CT/MRI every 8 weeks 5 TABLE OF CONTENTS 1. OBJECTIVES ..............................................................................................................................8 1.1 Primary Objectives .........................................................................................................8 1.2 Secondary Objectives.....................................................................................................8 2. BACKGROUND .........................................................................................................................8 2.1 Study Disease – Leiomyosarcoma of the uterus .......................................................8 2.2 CTEP IND Agent .....................................................................................................9 2.3 Other Agent(s) .......................................................................................................13 2.4 Summary of Nivolumab and ipilimumab combination data ..................................14 2.5 Rationale ................................................................................................................15 2.6 Correlative Studies Background ............................................................................16 3. PATIENT SELECTION ............................................................................................................17 3.1 Eligibility Criteria ..................................................................................................17 3.1.1 Patients must have histologically or cytologically confirmed advanced leiomyosarcoma of the uterus (ULMS). Advanced ULMS is defined as metastatic ULMS or unresectable primary ULMS. ...............................................17 3.2 Exclusion Criteria ..................................................................................................19 3.3 Inclusion of Women and Minorities ......................................................................21 4 REGISTRATION PROCEDURES (Rostered Protocol Model) ........................................21 4.1 Investigator and Research Associate Registration with CTEP ..............................21 4.2 Site Registration .....................................................................................................22 4.3 Patient Registration ................................................................................................24 4.4 General Guidelines .................................................................................................25 5 TREATMENT PLAN ........................................................................................................25 5.1 Agent Administration .............................................................................................25 5.2 Definition of Dose-Limiting Toxicity ....................................................................27 5.3 General Concomitant Medication and Supportive Care Guidelines ......................27 5.4 Duration of Therapy ...............................................................................................27 5.5 Duration of Follow Up ...........................................................................................29 5.6 Criteria for Removal from Study ...........................................................................29 5.7 Criteria to Resume Treatment ................................................................................29 5.8 Treatment of Nivolumab or Ipilimumab Related Infusion Reactions ...................31 5.9 Treatment Beyond Progression ..............................................................................32 6 DOSING DELAYS/DOSE MODIFICATIONS................................................................33 7 ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS ............................39 7.1 Comprehensive Adverse Events and Potential Risks Lists (CAEPRs) .................40 7.2 Adverse Event Characteristics ...............................................................................51 7.3 Expedited Adverse Event Reporting ......................................................................52 7.4 Routine Adverse Event Reporting .........................................................................54 7.5 Secondary Malignancy ...........................................................................................54 6 NCI Protocol #:9672 Version Date: 27April 2018 7.6 Second Malignancy ................................................................................................54 8 PHARMACEUTICAL INFORMATION ..........................................................................54 8.1 CTEP IND Agent(s) ...............................................................................................55 9 BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES ........................................59 9.1 Integrated Laboratory or Imaging Studies .............................................................59 9.2 Exploratory/Ancillary Correlative Studies ............................................................62 9.3 Integral Correlative Studies ...................................................................................64 10 STUDY CALENDAR .......................................................................................................65 11 MEASUREMENT OF EFFECT........................................................................................69 11.1 Antitumor Effect – Solid Tumors ..........................................................................69 11.2 Antitumor Effect – Hematologic Tumors ..............................................................75 11.3 Other Response Parameters ...................................................................................75 12 DATA REPORTING / REGULATORY REQUIREMENTS ...........................................76 12.1 Data Reporting .......................................................................................................76 12.2 CTEP Multicenter Guidelines ................................................................................78 12.3 Collaborative Agreements Language .....................................................................78 13 STATISTICAL
Load more

Recommended publications
  • A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary ORIGINAL RESEARCH Adenoma Preoperatively
    A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary ORIGINAL RESEARCH Adenoma Preoperatively A. Gutenberg BACKGROUND AND PURPOSE: Autoimmune hypophysitis (AH) mimics the more common nonsecret- J. Larsen ing pituitary adenomas and can be diagnosed with certainty only histologically. Approximately 40% of patients with AH are still misdiagnosed as having pituitary macroadenoma and undergo unnecessary I. Lupi surgery. MR imaging is currently the best noninvasive diagnostic tool to differentiate AH from V. Rohde nonsecreting adenomas, though no single radiologic sign is diagnostically accurate. The purpose of this P. Caturegli study was to develop a scoring system that summarizes numerous MR imaging signs to increase the probability of diagnosing AH before surgery. MATERIALS AND METHODS: This was a case-control study of 402 patients, which compared the presurgical pituitary MR imaging features of patients with nonsecreting pituitary adenoma and controls with AH. MR images were compared on the basis of 16 morphologic features besides sex, age, and relation to pregnancy. RESULTS: Only 2 of the 19 proposed features tested lacked prognostic value. When the other 17 predictors were analyzed jointly in a multiple logistic regression model, 8 (relation to pregnancy, pituitary mass volume and symmetry, signal intensity and signal intensity homogeneity after gadolin- ium administration, posterior pituitary bright spot presence, stalk size, and mucosal swelling) remained significant predictors of a correct classification. The diagnostic score had a global performance of 0.9917 and correctly classified 97% of the patients, with a sensitivity of 92%, a specificity of 99%, a positive predictive value of 97%, and a negative predictive value of 97% for the diagnosis of AH.
    [Show full text]
  • Autoimmune Adrenal Insufficiency in Celiac Disease
    International Journal of Celiac Disease, 2016, Vol. 4, No. 3, xx Available online at http://pubs.sciepub.com/ijcd/4/3/5 ©Science and Education Publishing DOI:10.12691/ijcd-4-3-5 Autoimmune Adrenal Insufficiency in Celiac Disease Hugh J Freeman* Department of Medicine (Gastroenterology), UBC Hospital, Vancouver, BC, Canada *Corresponding author: [email protected] Abstract Celiac disease is an immune-mediated intestinal disorder that may be associated with other immune- mediated extra-intestinal disorders, including immune-mediated endocrine diseases, such as autoimmune thyroiditis, most often with hypothyroidism. Other monoglandular autoimmune endocrine disorders may also occur, including autoimmune adrenal insufficiency (Addison’s disease). In celiac disease, clinical features of adrenal failure may be limited, difficult to differentiate from symptoms that might be attributed to celiac disease, or even life-threatening. In others with celiac disease, a polyglandular autoimmune syndrome has also been reported. Recent screening studies from multiple countries, particularly in Europe, have indicated that patients with autoimmune adrenal failure or Addison’s disease should be carefully screened for occult or silent celiac disease. Up to 10% of Addisonian patients may be serologically positive and histopathological features of untreated celiac disease may be detected, even with clinically occult intestinal disease. Celiac disease patients with a monoglandular autoimmune disorder should also be followed carefully for the later appearance of other autoimmune endocrine disorders as these may not all appear at the time of diagnosis of celiac disease, but sporadically during the life-long clinical course of celiac disease. Keywords: Addison’s Disease, Autoimmune Adrenal Insufficiency, Celiac Disease, Hypothyroidism, Polyglandular Endocrine Failure Cite This Article: Hugh J Freeman, “Autoimmune Adrenal Insufficiency in Celiac Disease.” International Journal of Celiac Disease, vol.
    [Show full text]
  • Novel Autoantigens in Autoimmune Hypophysitis
    Clinical Endocrinology (2008) 69, 269 –278 doi: 10.1111/j.1365-2265.2008.03180.x ORIGINAL ARTICLE NovelBlackwell Publishing Ltd autoantigens in autoimmune hypophysitis Isabella Lupi*, Karl W. Broman†, Shey-Cherng Tzou*, Angelika Gutenberg*‡, Enio Martino§ and Patrizio Caturegli*¶ *Department of Pathology, The Johns Hopkins University, School of Medicine, Baltimore, MD, USA, †Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA, ‡Department of Neurosurgery, Georg-August University, Göttingen, Germany, §Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy and ¶Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA although the performance was still inadequate to make immuno- Summary blotting a clinically useful test. Conclusion The study reports two novel proteins that could act Background Pituitary autoantibodies are found in autoimmune as autoantigens in autoimmune hypophysitis. Further studies are hypophysitis and other conditions. They are a marker of pituitary needed to validate their pathogenic role and diagnostic utility. autoimmunity but currently have limited clinical value. The methods used for their detection lack adequate sensitivity and (Received 8 November 2007; returned for revision 5 December 2007; specificity, mainly because the pathogenic pituitary autoantigen(s) finally revised 20 December 2007; accepted 20 December 2007) are not known and therefore antigen-based immunoassays have
    [Show full text]
  • S2 Table. List of Syntax for 96 Diseases
    S2 Table. List of syntax for 96 diseases 'autoimmune gastritis'/exp OR 'acantholysis'/exp OR 'acantholysis' OR 'acute disseminated encephalomyelitis'/exp OR 'adem (acute disseminated encephalomyelitis)' OR 'acute disseminated encephalitis' OR 'acute disseminated encephalomyelitis' OR 'encephalitis postvaccinalis' OR 'encephalitis, post-vaccinal' OR 'encephalomyelitis, acute disseminated' OR 'post vaccinal encephalitis' OR 'post vaccination encephalitis' OR 'post-infectious encephalitis' OR 'post-infectious encephalomyelitis' OR 'postinfection encephalitis' OR 'postinfectious encephalitis' OR 'postinfectious encephalomyelitis' OR 'postvaccinal encephalitis' OR 'postvaccinal encephalopathy' OR 'postvaccination encephalitis' OR 'postvaccine encephalitis' OR 'postvaccinial encephalitis' OR 'postvaccinial encephalomyelitis' OR 'smallpox vaccination encephalitis' OR 'vaccinal encephalitis' OR 'vaccination encephalopathy' OR 'vaccination post vaccinial encephalitis' OR 'vaccinia encephalitis' OR 'addison disease'/exp OR 'addison disease' OR 'addison`s disease' OR 'addisons disease' OR 'addison biermer disease' OR 'adult onset still disease'/exp OR 'adult onset still disease' OR 'still`s disease, adult- onset' OR 'allergic glomerulonephritis'/exp OR 'allergic glomerulonephritis' OR 'glomerulonephritis, allergic' OR 'glomerulonephritis, poststreptococcal' OR 'post streptococcal glomerulonephritis' OR 'poststreptococcal glomerulonephritis' OR 'anca associated vasculitis'/exp OR 'anca associated vasculitis' OR 'anca vasculitis' OR 'anca-associated
    [Show full text]
  • Hypophysitis
    3 179 M N Joshi and others Hypophysitis 179:3 R151–R163 Review MECHANISMS IN ENDOCRINOLOGY Hypophysitis: diagnosis and treatment Mamta N Joshi1, Benjamin C Whitelaw2,3 and Paul V Carroll1,3 Correspondence 1Department of Endocrinology, Guy’s & St. Thomas’ NHS Foundation Trust, London, UK, 2Department of should be addressed Endocrinology, Kings College Hospital NHS Foundation Trust, London, UK, and 3Faculty of Life Sciences & Medicine, to P V Carroll King’s College Hospital London, London, UK Email [email protected] Abstract Hypophysitis is a rare condition characterised by inflammation of the pituitary gland, usually resulting in hypopituitarism and pituitary enlargement. Pituitary inflammation can occur as a primary hypophysitis (most commonly lymphocytic, granulomatous or xanthomatous disease) or as secondary hypophysitis (as a result of systemic diseases, immunotherapy or alternative sella-based pathologies). Hypophysitis can be classified using anatomical, histopathological and aetiological criteria. Non-invasive diagnosis of hypophysitis remains elusive, and the use of currently available serum anti-pituitary antibodies are limited by low sensitivity and specificity. Newer serum markers such as anti-rabphilin 3A are yet to show consistent diagnostic value and are not yet commercially available. Traditionally considered a very rare condition, the recent recognition of IgG4-related disease and hypophysitis as a consequence of use of immune modulatory therapy has resulted in increased understanding of the pathophysiology of hypophysitis. Modern imaging techniques, histological classification and immune profiling are improving the accuracy of the diagnosis of the patient with hypophysitis. The objective of this review is to bring readers up-to- date with current understanding of conditions presenting as hypophysitis, focussing on recent advances and areas for future development.
    [Show full text]
  • Ramos-Casals, Et Al. 2020
    PRIMER Immune- related adverse events of checkpoint inhibitors Manuel Ramos- Casals1,2,3 ✉ , Julie R. Brahmer4, Margaret K. Callahan5,6,7, Alejandra Flores- Chávez2, Niamh Keegan5, Munther A. Khamashta8, Olivier Lambotte9,10, Xavier Mariette11, Aleix Prat12,13 and Maria E. Suárez- Almazor14 Abstract | Cancer immunotherapies have changed the landscape of cancer treatment during the past few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and CTLA-4, are increasingly used for certain cancers; however, this increased use has resulted in increased reports of immune- related adverse events (irAEs). These irAEs are unique and are different to those of traditional cancer therapies, and typically have a delayed onset and prolonged duration. IrAEs can involve any organ or system. These effects are frequently low grade and are treatable and reversible; however, some adverse effects can be severe and lead to permanent disorders. Management is primarily based on corticosteroids and other immunomodulatory agents, which should be prescribed carefully to reduce the potential of short- term and long- term complications. Thoughtful management of irAEs is important in optimizing quality of life and long- term outcomes. Cancer immunotherapies are broadly defined as thera- that is not dependent on individual cancer- specific anti- pies that directly or indirectly target any component of gens2. The use of ICIs for cancer therapy is increasing; the immune system that is involved in the anti- cancer however, a key challenge that has emerged with the immune response, including the stimulation, enhance- progressive implementation of ICIs in clinical practice ment, suppression or desensitization of the immune sys- is their uncontrolled collateral effects on the immune tem.
    [Show full text]
  • Growth Hormone Impaired Secretion and Antipituitary Antibodies In
    Eur J Pediatr (2006) 165:897–903 DOI 10.1007/s00431-006-0182-4 ORIGINAL PAPER Growth hormone impaired secretion and antipituitary antibodies in patients with coeliac disease and poor catch-up growth after a long gluten-free diet period: a causal association? Lorenzo Iughetti & Annamaria De Bellis & Barbara Predieri & Antonio Bizzarro & Michele De Simone & Fiorella Balli & Antonio Bellastella & Sergio Bernasconi Received: 7 February 2006 / Revised: 5 May 2006 / Accepted: 9 May 2006 / Published online: 3 August 2006 # Springer-Verlag 2006 Abstract 130 patients aged 1–15 years. Seven CD children, without Introduction Coeliac disease (CD) is usually associated catch-up growth after at least 12-months GFD, were tested with impaired growth in children. A gluten-free diet (GFD) for GH secretion and, in five out of seven patients, the induces a catch-up growth with the recovery of height in diagnosis of GHD was made in the absence of metabolic about 2 years. and systemic diseases. Aim and discussion The lack of the height improvement Results APA and antihypothalamus antibodies were has been related to growth hormone (GH) secretion detected by the indirect immunofluorescence method in impairment. CD is an autoimmune disease often associated the seven CD children without catch-up growth factor and with other endocrine and non-endocrine autoimmune in 25 CD children without growth impairment matched for disease. The aim of this study was to evaluate antipituitary sex and age, and in 58 healthy children as control groups. autoantibodies (APA) and antihypothalamus autoantibodies APA resulted positive at high titres in four out of five CD- in CD children with poor clinical response to a GFD and GHD patients and were also positive at low titres (<1:8) in growth hormone deficiency (GHD).
    [Show full text]
  • Lymphocytic Hypo- Physitis in a Patient with Systemic Lupus Erythematosus
    CASE REPORT Clinical and Experimental Rheumatology 2000; 18: 78-80. Lymphocytic hypo- ABSTRACT mass and the pathologic findings during A case of lymphocytic hypophysitis in a a transsphenoidal operation were com- physitis in a patient patient with systemic lupus erythema- patible with lymphocytic hypophysitis. tosus is described. A 20-year-old We describe an SLE patient with head- with systemic lupus woman was admitted to our hospital ache and nausea, in whom the presence with generalized myalgia and facial of an intrasellar mass and pathologic erythematosus rash in May 1998. The patient had a findings indicated lymphocytic hypo- medical history, physical examination, physitis. J.D. Ji1, S.Y. Lee2, and laboratory findings compatible 2 2 with systemic lupus erythematosus Case report S.J. Choi , Y.H. Lee , (SLE). Headache and nausea had A 20-year-old woman was admitted to G.G. Song2 developed 3 months previously and the Korea University Anam Hospital in worsened over the following months. May 1998 with a three-month history of 1Hospital for Rheumatic Disease, Hanyang Hormonal investigation showed hypo- facial rash, fever, generalized myalgia, University Medical Center; 2Division of pituitarism except for prolactin. A hair loss and arthralgia. During the three Rheumatology, Department of Internal magnetic resonance image of the brain months before admission, she had noted Medicine, Korea University Hospital, showed a mass lesion in the pituitary intermittent headache and nausea. No Seoul, Korea. fossa. A trans-sphenoidal surgical visual disturbances were present. There Jong Dae Ji, MD; So Young Lee, MD; procedure was performed which was no family history of autoimmune or Seong Jae Choi, MD; Young Ho Lee, MD, revealed a dark-yellowish hematoma.
    [Show full text]
  • Acquired Aplastic Anemia • Acute Disseminated Encephalomyelitis
    • Acquired aplastic anemia • Acute disseminated encephalomyelitis (ADEM) • Acute hemorrhagic leukoencephalitis (AHLE) / Hurst’s disease • Agammaglobulinemia, primary • Alopecia areata • Ankylosing spondylitis (AS) • Anti-NMDA receptor encephalitis • Antiphospholipid syndrome (APS) • Arteriosclerosis • Autism spectrum disorders (ASD) • Autoimmune Addison’s disease (AAD) • Autoimmune dysautonomia / Autoimmune autonomic ganglionopathy (AAG) • Autoimmune encephalitis • Autoimmune gastritis • Autoimmune hemolytic anemia (AIHA) • Autoimmune hepatitis (AIH) • Autoimmune hyperlipidemia • Autoimmune hypophysitis / lymphocytic hypophysitis • Autoimmune inner ear disease (AIED) • Autoimmune lymphoproliferative syndrome (ALPS) • Autoimmune myocarditis • Autoimmune oophoritis • Autoimmune orchitis • Autoimmune pancreatitis (AIP) / Immunoglobulin G4-Related Disease (IgG4-RD) • Autoimmune polyglandular syndromes, Types I, II, & III • Autoimmune progesterone dermatitis • Autoimmune sudden sensorineural hearing loss (SNHL) • Balo disease • Behçet’s disease • Birdshot chorioretinopathy / birdshot uveitis • Bullous pemphigoid • Castleman disease • Celiac disease • Chagas disease • Chronic fatigue syndrome (CFS) / myalgic encephalomyelitis (ME) • Chronic inflammatory demyelinating polyneuropathy (CIDP) • Chronic Lyme disease / post-treatment Lyme disease syndrome (PTLDS) • Chronic urticaria (CU) www.Stemedix.com 601 7th Street South, Suite 565 T: 800-531-0831 [email protected] Saint Petersburg, FL 33701 F: 727-362-4630 • Churg-Strauss syndrome / eosinophilic
    [Show full text]
  • Autoimmune Hypophysitis: a Single Centre Experience Menon S K, Sarathi V, Bandgar T R, Menon P S, Goel N, Shah N S
    Original Article Singapore Med J 2009; 50(11) : 1080 Autoimmune hypophysitis: a single centre experience Menon S K, Sarathi V, Bandgar T R, Menon P S, Goel N, Shah N S ABSTRACT estimated incidence of AH is one in nine million per year.(2) Introduction: Autoimmune hypophysitis (AH) is a It occurs predominantly in young females, especially rare primary autoimmune inflammatory disorder in the peripartum period.(3) The classical presentation is involving the pituitary gland. symptoms of sellar mass with or without varying degrees of hypopituitarism. The patients may have evidence of Methods: A retrospective analysis of the clinical other associated autoimmune diseases.(4) Histopathology is features and outcome of patients diagnosed with required for a definitive diagnosis, but many cases have been AH between 1988 and 2006, was carried out. managed solely on clinical grounds.(3) The natural history of this disease, which ranges from spontaneous recovery to Results: 15 patients (14 females and one male) with death due to unrecognised hypocortisolism, is still elusive. AH were identified. Three patients presented in To add to the scant but valuable information regarding AH, the peripartum period. Headache, vomiting and we present our experience with this disease. visual field defects, suggestive of an expanding sellar mass, were the most common presenting MEthoDS symptoms (67 percent). The most common The endocrinology department clinical register from a deficient hormone was adrenocorticotropic tertiary care centre in western India was searched for hormone (ACTH) (67 percent), followed by cases of AH diagnosed between 1988 and 2006. The thyroid stimulating hormone (53 percent) and diagnosis of AH was based on the following criteria: gonadotropins (40 percent).
    [Show full text]
  • Rheumatologic Complications of Immune Checkpoint Blockade
    RHEUMATOLOGIC COMPLICATONS OF IMMUNE CHECKPOINT BLOCKADE And other things we should know What happens when you “release the brakes”? OSCAR ARILL, M.D. Immune Checkpoint Inhibitors Pembrolizumab Metastatic melanoma Rheumatologic Complications of Immune Checkpoint Blockade DISCLOSURES Nothing to disclose I am not an oncologist Off-label use of DMARD’s Rheumatology Consult A 74 y/o man followed in the Hema-Onco Clinic for a right upper lobe sarcomatoid epithelioid lung carcinoma with adenocarcinoma component, stage IIIB A rheumatology consult was requested due to persistently severe inflammatory arthritis affecting his hands, along with a scalp rash The patient was evaluated in the Rheumatology clinic 10-27-2017 His previous therapy included two cycles of immune checkpoint inhibitor, Nivolumab (anti-PD-1) during May/June/ 2017 After two cycles severe pain and edema involving both hands developed along with a scaly rash on his occiput area His labs showed a negative RF and a negative ANA, ESR 50, CRP 6.7 mg/L Rheumatology Consult When evaluated the patient presented findings of erosive osteoarthritis with severe superimposed inflammatory changes which were worse in his PIPs and DIPs The patient had been treated in the Hema-Onco Clinic with steroids with significant improvement, but the inflammatory arthritis recurred upon tapering and discontinuation of the steroids Radiographs of the hands done 19.5 months apart showed erosive changes that had progressed The rheumatology recommendation was to re-start corticosteroids, starting
    [Show full text]
  • Autoimmune Hypophysitis with Late Renal Involvement: a Case Report
    Case Report Autoimmune Hypophysitis with Late Renal Involvement: A Case Report Stefano Iuliano 1 , Maria Carmela Zagari 1, Margherita Vergine 1, Alessandro Comi 2, Michele Andreucci 3, Gemma Patella 3, Stefania Giuliano 2, Sandro La Vignera 4 , Antonio Brunetti 3 , Antonio Aversa 1,* and Emanuela A. Greco 3 1 Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy; [email protected] (S.I.); [email protected] (M.C.Z.); [email protected] (M.V.) 2 Azienda Ospedaliero-Universitaria MaterDomini, Policlinico Universitario Germaneto, 88100 Catanzaro, Italy; [email protected] (A.C.); [email protected] (S.G.) 3 Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy; [email protected] (M.A.); [email protected] (G.P.); [email protected] (A.B.); [email protected] (E.A.G.) 4 Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy; [email protected] * Correspondence: [email protected] Abstract: We report a case of a 50-year-old male admitted to the Endocrinology Unit because of persistent headaches, nausea, feeling tired, sudden weight loss, cold intolerance, decreased appetite, and lack of sex interest. Diagnostic workup showed a 6-millimeter pituitary tumor without signs of compression, and a condition of progressive panhypopituitarism. After 12 months of hormone re- Citation: Iuliano, S.; Zagari, M.C.; placement therapy, the patient was hospitalized because of sudden weight gain, periorbital-peripheral Vergine, M.; Comi, A.; Andreucci, M.; edema, severe dyslipidemia, hypertension, and proteinuria. Corticosteroid therapy was shifted from Patella, G.; Giuliano, S.; La Vignera, oral to continuous intravenous infusion, and once the diagnosis of “immune complex-mediated S.; Brunetti, A.; Aversa, A.; et al.
    [Show full text]